Document ID: chunk:federal_register_of_legislation:F2024C00988:front:0:p3
Version: federal_register_of_legislation:F2024C00988
Segment Type: other
Provision Reference: 
Character Range: 5881–9130

charge for delivery
Part 6—Other matters relating to prescriptions and supply etc.
58 Purpose of this Part
59 Keeping documents—other than for continued dispensing supplies or medication chart prescriptions
60 Keeping documents—continued dispensing supplies
61 Keeping documents—medication chart prescriptions
62 Proper stocks to be kept
63 Standards of composition and purity of pharmaceutical benefits and ingredients
64 Labelling of pharmaceutical benefits—full cost
65 Surrender of forms
Part 7—Price reduction, price disclosure and stockholding
Division 1—Price reduction
65A Price reductions for single brands of combination items
66 Reduction day
Division 2—Price disclosure
Subdivision A—Interpretation
67 Meaning of data collection period
68 Meaning of price sampling day
69 Special rules for certain listed brands
Subdivision B—Weighted average disclosed price
70 Method for determining weighted average disclosed price of listed brand of pharmaceutical item
71 Step 1—net revenue for brand
72 Step 2—adjusted volume for brand
73 Step 3—average approved ex‑manufacturer price for brand
73A Step 3A—adjusted net revenue for brand
74 Step 4—disclosed price for brand
75 Step 5—price percentage difference of brand
76 Step 6—repeat steps for each brand of pharmaceutical item
77 Step 7—total adjusted volume of brands of pharmaceutical item
78 Step 8—weighted average percentage difference of brands of pharmaceutical item
79 Step 9—repeat steps for each pharmaceutical item with related brands
80 Step 10—weighted average percentage difference for listed brand and all related brands
81 Step 11—weighted average disclosed price for listed brand of pharmaceutical item
82 When weighted average disclosed price is the same as the applicable approved ex‑manufacturer price
Subdivision C—Information that must not be taken into account
83 Information that must not be taken into account
84 Originator brands
Subdivision D—Price disclosure requirements
85 Price disclosure requirements
Subdivision E—Price reduction
85A Flow on price reductions for brands of combination items
Division 3—Stockholding requirements
85B Usual demand for a brand
85C Stockholding disclosure requirements
Part 8—Arrangements for the Pharmaceutical Benefits Advisory Committee
Division 1—Matters relating to the appointment of members of the Committee
86 Nominating bodies
87 Number of nominations for appointment
88 Resignation
Division 2—Matters relating to the procedure of the Committee
89 Purpose of this Division
90 Presiding member
91 Meetings of the Committee
92 Quorum
93 Voting
94 Disclosure of pecuniary interests by members
95 Resolutions without a formal meeting
96 Reports and recommendations
Division 3—Matters relating to sub‑committees
97 Remuneration for chair and members of sub‑committees
Part 9—Application, savings and transitional provisions
98 Definitions
99 Things done under old regulations
102 Transitional provision relating to the National Health (Pharmaceutical Benefits) Amendment (Active Ingredient Prescribing) Regulations 2019
103 Application provision relating to the National Health (Pharmaceutical Benefits) Amendment (2021 Measures No. 1) Regulations 2021
104 Transitional provision relating to the National Health (Pharmaceutical